MedTrace Logo

Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone

NCT03751111 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2025-04-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of sublingual naloxone in the treatment of chronic itch in patients under arsenic exposure.

Conditions

  • Chronic Pruritus

Interventions

DRUG

Naloxone

Naloxone at an sublingual dose of 0.4 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.

DRUG

Placebo

Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Yi Xiao, Ph.D · Xiangya Hospital of Central South University

  • Minxue Shen, Ph.D · Xiangya Hospital of Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-13
Primary Completion
2019-03-01
Completion
2019-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03751111 on ClinicalTrials.gov